Shares of Coherus Biosciences Inc (NASDAQ:CHRS) have received a consensus recommendation of “Buy” from the ten analysts that are presently covering the firm, Marketbeat reports. Two research analysts have rated the stock with a sell rating and seven have assigned a buy rating to the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $30.29.
A number of equities research analysts have recently commented on the stock. ValuEngine cut shares of Coherus Biosciences from a “sell” rating to a “strong sell” rating in a report on Thursday, October 10th. TheStreet upgraded shares of Coherus Biosciences from a “d-” rating to a “c-” rating in a research note on Thursday, November 7th. HC Wainwright restated a “buy” rating and issued a $29.00 price objective on shares of Coherus Biosciences in a research note on Monday, November 25th. Credit Suisse Group reissued a “buy” rating and issued a $36.00 price target on shares of Coherus Biosciences in a report on Friday, November 8th. Finally, Barclays set a $31.00 price target on shares of Coherus Biosciences and gave the company a “buy” rating in a report on Monday, August 12th.
Shares of NASDAQ:CHRS traded up $0.46 on Wednesday, reaching $18.45. The company’s stock had a trading volume of 120,310 shares, compared to its average volume of 1,106,165. The stock’s 50-day moving average is $18.35 and its two-hundred day moving average is $19.49. Coherus Biosciences has a 52-week low of $8.32 and a 52-week high of $23.91. The company has a debt-to-equity ratio of 3.37, a current ratio of 3.34 and a quick ratio of 3.25. The stock has a market capitalization of $1.26 billion, a P/E ratio of -5.73 and a beta of 2.88.
In related news, CFO Jean-Frederic Viret sold 3,159 shares of the company’s stock in a transaction dated Wednesday, September 18th. The shares were sold at an average price of $20.44, for a total transaction of $64,569.96. Following the transaction, the chief financial officer now owns 11,672 shares in the company, valued at approximately $238,575.68. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, COO Vincent R. Anicetti sold 2,500 shares of the company’s stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $20.03, for a total transaction of $50,075.00. Following the transaction, the chief operating officer now owns 21,810 shares in the company, valued at $436,854.30. The disclosure for this sale can be found here. In the last quarter, insiders have sold 847,217 shares of company stock worth $15,281,972. 18.20% of the stock is owned by corporate insiders.
A number of institutional investors have recently added to or reduced their stakes in CHRS. Cutler Group LP acquired a new position in Coherus Biosciences during the 3rd quarter valued at about $32,000. Tower Research Capital LLC TRC acquired a new position in Coherus Biosciences during the third quarter valued at approximately $52,000. Public Employees Retirement System of Ohio acquired a new position in Coherus Biosciences during the second quarter valued at approximately $75,000. Aperio Group LLC acquired a new position in Coherus Biosciences during the second quarter valued at approximately $80,000. Finally, Bank of Montreal Can acquired a new position in Coherus Biosciences during the second quarter valued at approximately $114,000. Institutional investors own 99.08% of the company’s stock.
About Coherus Biosciences
Coherus BioSciences, Inc, a commercial-stage biotherapeutics company, focuses on the biosimilar market worldwide. It markets UDENYCA, a long-acting granulocyte-colony stimulating factor, which stimulates production of granulocytes in order to promote the body's ability to fight infections. The company sells UDENYCA in the United States.
Receive News & Ratings for Coherus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coherus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.